| Name | Title | Contact Details |
|---|
Evofem, Inc. is a privately held biotechnology company that discovers, develops and commercializes prescription and over-the-counter products in the areas of feminine care, contraception, and the prevention of sexually transmitted infections. Evofem, Inc. is committed to delivering effective, woman-controlled, rapidly reversible forms of contraception to women globally. In February 2013, Evofem entered into a strategic alliance with Woman Care Global, a nonprofit organization whose mission is to provide access to quality, affordable, women`s healthcare products through a sustainable value chain in over 100 countries, with a particular focus on under-served markets in Africa, Asia, and Latin America. Through this alliance, Woman Care Global provides sales, marketing and global distribution support to Evofem`s products.
Trimline Medical Products Corp is a Branchburg, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cardica is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SANUWAVE, Inc. is an emerging leader in the development and commercialization of noninvasive, biological response activating devices in the regenerative medicine area for the repair and regeneration of tissue, musculoskeletal and vascular structures. SANUWAVE`s portfolio of products and product candidates activate biologic signaling and angiogenic reponses, including revascularization and microcirculation, helping to restore the body`s normal healing processes and regeneration. These devices, based on Pulsed Acoustic Cellular Expression (PACE™) technology, are being developed and commercialized for use in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions.
Advanced Cardiac Therapeutics, Inc. is a pre-commercial, medical device company that designs and manufactures a catheter-based system for the treatment of patients with AFIB. AFIB is characterized by an irregular, often rapid heart rate that commonly causes poor systemic blood flow. The Company`s mission is to dramatically improve the treatment of AFIB through the introduction of products based on its proprietary catheter and generator system. ACT`s technology is the only system in the world to leverage feedback from four unique capabilities: temperature sensing, low irrigation flow rates, high resolution EGM attenuation and contact sensing. The ACT system is not currently approved for commercial use.